CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxicity and comparable efficacy ...
CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.The safety pro ...
Science Daily12h
Novel pathway has potential to slow progression of pulmonary fibrosis
Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor that senses mechanical ...
Nearly 4 million lung cancer deaths averted and 76 million years of life gained due to tobacco control in US
New research led by American Cancer Society (ACS) researchers estimates more than 3.8 million lung cancer deaths were averted ...
Rheumatology Advisor19h
Interstitial Lung Abnormalities in PRISm Linked to Greater Mortality Risk
Interstitial lung abnormalities are more prevalent in individuals with PRISm, and those with PRISm and ILAs have higher all-cause mortality.
Liverwurst, Jell-O become unlikely teaching tools at Gwynedd Mercy University for respiratory therapy students
Respiratory therapy students at Gwynedd Mercy University are using liverwurst to perfect their biopsy techniques.
AHA/ASA Journals22h
XBP1s-EDEM2 Prevents the Onset and Development of HFpEF by Ameliorating Cardiac Lipotoxicity
BACKGROUND: Morbidity and mortality of heart failure with preserved ejection fraction (HFpEF) is increased in metabolic disorders. However, options for preventing and treating these prevalent outcomes ...